SG162615A1 - Bazedoxifene treatment regimens - Google Patents

Bazedoxifene treatment regimens

Info

Publication number
SG162615A1
SG162615A1 SG200608134-3A SG2006081343A SG162615A1 SG 162615 A1 SG162615 A1 SG 162615A1 SG 2006081343 A SG2006081343 A SG 2006081343A SG 162615 A1 SG162615 A1 SG 162615A1
Authority
SG
Singapore
Prior art keywords
bazedoxifene
treatment regimens
dosing
hypercholesteremia
azepan
Prior art date
Application number
SG200608134-3A
Other languages
English (en)
Inventor
Simon N Jenkins
Barry S Komm
James C Ermer
Mark A Collins
Geraldine M Ferron
Pol Boudes
Wendy A Dulin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG162615A1 publication Critical patent/SG162615A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
SG200608134-3A 2002-06-13 2003-06-13 Bazedoxifene treatment regimens SG162615A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13

Publications (1)

Publication Number Publication Date
SG162615A1 true SG162615A1 (en) 2010-07-29

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200608134-3A SG162615A1 (en) 2002-06-13 2003-06-13 Bazedoxifene treatment regimens

Country Status (20)

Country Link
US (1) US20040063692A1 (fr)
EP (1) EP1531807A4 (fr)
JP (1) JP2005531613A (fr)
KR (1) KR20050010886A (fr)
CN (1) CN1658868A (fr)
AU (1) AU2003248707A1 (fr)
BR (1) BR0311774A (fr)
CA (1) CA2489098A1 (fr)
CR (1) CR7585A (fr)
EC (1) ECSP045492A (fr)
IL (1) IL165210A0 (fr)
MX (1) MXPA04011634A (fr)
NI (1) NI200400065A (fr)
NO (1) NO20044954L (fr)
NZ (1) NZ537051A (fr)
RU (1) RU2355397C2 (fr)
SG (1) SG162615A1 (fr)
UA (1) UA85374C2 (fr)
WO (1) WO2003105834A1 (fr)
ZA (1) ZA200409991B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006123939A (ru) * 2004-01-13 2008-02-20 Вайет (Us) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
CA2561124A1 (fr) * 2004-04-08 2005-10-27 Wyeth Formulations a dispersion solide d'acetate de bazedoxifene
WO2005100315A1 (fr) * 2004-04-08 2005-10-27 Wyeth Ascorbate de bazedoxifene utile en tant que modulateur selectif des recepteurs d'oestrogene
WO2006104791A1 (fr) * 2005-03-31 2006-10-05 Wyeth Produit combine a base d'o-desmethylvenlafaxine et de bazedoxifene et utilisations de ce produit
EP1898888A2 (fr) * 2005-06-29 2008-03-19 Wyeth a Corporation of the State of Delaware Formulations d'oestrogenes conjugues et de bazedoxifene
KR20140088917A (ko) * 2005-08-24 2014-07-11 와이어쓰 엘엘씨 바제독시펜 아세테이트 제형 및 이의 제조방법
WO2008067387A2 (fr) * 2006-11-29 2008-06-05 Wyeth Comprimés bicouches d'œstrogène/serm et œstrogène/progestine
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (fr) * 2012-06-07 2013-12-12 Zentiva, K. S. Procédé de préparation d'une formulation d'acétate de bazédoxifène sans anti-oxydant et stable du point de vue polymorphe et chimique
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
WO2002003991A2 (fr) * 2000-07-06 2002-01-17 Wyeth Methodes permettant d'accroitre l'activite d'oxyde nitrique- synthase
WO2002003992A2 (fr) * 2000-07-06 2002-01-17 Wyeth Therapie pour degenerescence osseuse en rapport avec une prothese

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli
SK281737B6 (sk) * 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
WO2002003991A2 (fr) * 2000-07-06 2002-01-17 Wyeth Methodes permettant d'accroitre l'activite d'oxyde nitrique- synthase
WO2002003992A2 (fr) * 2000-07-06 2002-01-17 Wyeth Therapie pour degenerescence osseuse en rapport avec une prothese

Also Published As

Publication number Publication date
MXPA04011634A (es) 2005-07-05
EP1531807A4 (fr) 2007-10-31
AU2003248707A1 (en) 2003-12-31
ZA200409991B (en) 2007-09-26
CA2489098A1 (fr) 2003-12-24
BR0311774A (pt) 2007-05-08
EP1531807A1 (fr) 2005-05-25
CN1658868A (zh) 2005-08-24
IL165210A0 (en) 2005-12-18
KR20050010886A (ko) 2005-01-28
RU2355397C2 (ru) 2009-05-20
ECSP045492A (es) 2005-03-10
CR7585A (es) 2008-10-03
JP2005531613A (ja) 2005-10-20
NI200400065A (es) 2005-08-09
US20040063692A1 (en) 2004-04-01
NZ537051A (en) 2007-11-30
UA85374C2 (en) 2009-01-26
NO20044954L (no) 2004-12-16
WO2003105834A1 (fr) 2003-12-24
RU2004136316A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
SG162615A1 (en) Bazedoxifene treatment regimens
PL365283A1 (en) Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
NZ503981A (en) Novel amines, pharmaceutical compositions containing these amines, and uses thereof
NO20031266D0 (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
IS1990B (is) Nýstárlegar staðgengnar hringamínósýrur notaðar til lyfjagerðar
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
BR9708180A (pt) Amoniácidos cíclicos em pontes como agentes farmacêuticos
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
DK1244435T5 (da) Polyhydroxylerede, aromatiske forbindelser til behandling af amyloidose og alpha-synuclein fibril sygdomme
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
MXPA05013711A (es) Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1.
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
YU2200A (sh) Termodinamički stabilna modifikacija 1-(4-karbazoliloksi)-3-/2-(2-metoksifenoksi)etilamino/-2-propanola, postupak za njeno dobijanje i farmaceutske smeše koje je sadrže
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
NO960332D0 (no) Tbp2 fragmenter av transferrinreseptoren av neisseria meningitidis
DK1187832T3 (da) Aminoheterocycler, som er anvendelige som farmaceutiske midler
PL337871A1 (en) Application of a specific antagonist of the 5 ht2 receptor in production of a drug useful in treating the sleep apnoea
BG105761A (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
DE69828998D1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
FR2845302B1 (fr) Appareil pour le vissage d'elements de fixation